New drug combo aims to stall advanced prostate cancer

NCT ID NCT07711002

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests whether adding the experimental drug saruparib to standard hormone therapy can slow the growth of metastatic hormone-sensitive prostate cancer. It includes men whose cancer has not progressed after prior chemotherapy or a specific type of radiation therapy. Participants are randomly assigned to receive either saruparib or a placebo, along with their usual hormone treatment, to see if the combination delays cancer spread and improves survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a drug called saruparib combined with a standard hormone therapy (enzalutamide, darolutamide, or abiraterone)
What this could lead to: If successful, this combination could delay cancer progression and extend survival for men with metastatic prostate cancer who have already received initial treatment.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. The drug may cause side effects or may not improve outcomes compared to standard therapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site

Ottawa, Ontario, K1H 7W9, Canada
Research Site

Montreal, Quebec, H2X 0A9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.